WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has announced plans to construct a new manufacturing base at the Tuas Biomedical Park in Singapore. This strategic expansion is designed to enhance the joint venture’s capacity to serve the global demand for research and development services and the manufacturing of antibody drug conjugates (ADCs) and other innovative drug conjugates.
The upcoming facility, spanning a total construction area of 22,000 square meters, will support end-to-end clinical and commercial manufacturing capabilities. The production line will have the dual capability to scale up manufacturing, with a potential scale of up to 2000 liters for antibody intermediates and 2000 liters for ADC coupling stock solution. The coupling agent production line will include one 10 square meter freeze-drying machine and two 30 square meter freeze-drying machines, which are set to boost the production capacity for liquid and freeze-dried agents, aiming for an annual output of over 8 million bottles. The new manufacturing base is projected to be operational by 2026.
This significant investment in infrastructure by WuXi XDC underscores the company’s commitment to advancing the field of biologics and enhancing its global footprint in the biopharmaceutical industry.- Flcube.com
